Waters AI Stock Analysis
Want to see WAT full AI Analyst Report?
Waters (WAT) AI Stock Analysis
Waters
(NYSE:WAT)
The score is held back primarily by weakened current (TTM) profitability and cash-flow conversion, despite solid longer-term cash generation and manageable leverage trends. Technicals are supportive with a strong trend above key moving averages and positive MACD. However, valuation is a major negative due to the extremely high P/E, partially offset by a notably upbeat earnings call with raised guidance and synergy/cost-savings progress.
Waters Key Performance Indicators (KPIs)
Total Recurring RevenueMeasures the revenue from ongoing customer subscriptions or services, indicating the stability and predictability of the company’s income stream.
Total recurring revenue shows steady, seasonal rises with clear step‑ups after the acquisition of Biosciences and Diagnostic Solutions; growth is accelerating as management pursues instrument replacements, service attachments and cross‑sell synergies. Q1 dips look cyclical rather than structural, and product/regulatory wins plus a $50M revenue‑synergy plan and 180‑day commercial push signal further recurring upside—but near‑term volatility from China/export constraints and respiratory testing weakness could temper quarter‑to‑quarter consistency until synergies fully scale.
Waters (WAT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $44.56B
- Dividend Yield
- ―
- Average Volume (3M)
- 829.66K
- Price to Earnings (P/E)
- 192.9
- Beta (1Y)
- 0.93
- Revenue Growth
- 80.68%
- EPS Growth
- -78.49%
- Country
- US
- Employees
- 15,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Waters Business Overview & Revenue Model
Company Description
Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactu...
How the Company Makes Money
Waters primarily makes money by selling analytical instrumentation and then generating recurring revenue from the installed base through consumables and services. Key revenue streams include: (1) Instrument sales: Revenue from capital equipment such...
Waters Earnings Call Summary
The call was strongly positive. Highlights significantly outweighed the challenges, with double-digit organic growth, a 21% adjusted EPS increase, raised full-year revenue and EPS guidance, improving acquired-business execution, strong product and AI momentum, cost-savings progress and a constructive 2027 framework. The main negatives were limited reported growth in the acquired businesses, China DRG and channel-inventory headwinds, constrained free cash flow, elevated inventory and acquisition-related costs.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, organic constant currency revenue growth guidance was raised 140 basis points at the midpoint to 9.1% to 9.7%, with organic reported revenue expected at $3.429 billion to $3.447 billion; Biosciences and Diagnostic Solutions revenue is expected to be approximately $3.05 billion, a $5 million raise, and total reported revenue is expected to be approximately $6.479 billion to $6.497 billion, a $43 million raise at the midpoint. Full year adjusted EBIT margin is expected to be 28.2%, net interest expense $196 million, the tax rate 15.4%, and adjusted earnings per fully diluted share $14.60 to $14.70, representing year-over-year growth of 11% to 12% and 13% to 14% in constant currency. Fourth quarter organic constant currency revenue growth is expected to be 7% to 9%, organic reported revenue $984 million to $1.002 billion, Biosciences and Diagnostic Solutions revenue approximately $817 million, total reported revenue $1.801 billion to $1.819 billion, and adjusted earnings per fully diluted share $4.58 to $4.68; on a days adjusted basis, guidance reflects 9% to 11% organic growth and approximately 10% reported growth for acquired businesses. For 2027, the starting assumption is legacy Waters growing high single digits and legacy BD growing mid-single digits, combining to mid-single-digit plus organic growth, with a critical path to a high single-digit growth potential for the combined company, 100 basis points of adjusted operating margin expansion to 29.2%, low teens adjusted EPS growth, and mid-teens as the upside case; revenue synergies are underwritten at another $60 million added in 2027 over and above the $50 million in 2026.
Waters Financial Statement Overview
Summary
Multi-year results show a profitable, cash-generative profile with improving leverage trends, but the latest TTM shows a sharp profitability reset (net and operating margins falling to low-single digits) and meaningfully lower free cash flow versus the prior year. Balance-sheet leverage appears manageable, yet the near-term earnings quality and return deterioration weighs heavily.
Income Statement
42NeutralBalance Sheet
55NeutralCash Flow
58Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.61B | 3.17B | 2.96B | 2.96B | 2.97B | 2.79B |
| Gross Profit | 2.77B | 1.88B | 1.76B | 1.76B | 1.72B | 1.63B |
| EBITDA | 1.13B | 1.01B | 1.04B | 1.00B | 1.02B | 982.81M |
| Net Income | 98.21M | 642.63M | 637.83M | 642.23M | 707.75M | 692.84M |
Balance Sheet | ||||||
| Total Assets | 24.11B | 5.08B | 4.55B | 4.63B | 3.28B | 3.09B |
| Cash, Cash Equivalents and Short-Term Investments | 593.00M | 587.83M | 325.36M | 395.97M | 481.39M | 569.28M |
| Total Debt | 5.50B | 1.49B | 1.70B | 2.44B | 1.66B | 1.60B |
| Total Liabilities | 8.82B | 2.52B | 2.73B | 3.48B | 2.78B | 2.73B |
| Stockholders Equity | 15.29B | 2.56B | 1.83B | 1.15B | 504.49M | 367.55M |
Cash Flow | ||||||
| Free Cash Flow | 291.58M | 539.81M | 619.64M | 442.18M | 428.20M | 579.01M |
| Operating Cash Flow | 460.55M | 652.55M | 762.12M | 602.81M | 611.66M | 747.27M |
| Investing Cash Flow | -39.13M | -152.25M | -144.02M | -1.44B | -107.97M | -231.63M |
| Financing Cash Flow | -276.66M | -237.21M | -696.67M | 754.95M | -509.63M | -438.27M |
Waters Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WAT, the sentiment is Neutral. The current price of 453.42 is below the 20-day moving average (MA) of 462.02, above the 50-day MA of 441.09, and above the 200-day MA of 373.61, indicating a neutral trend. The MACD of 6.21 indicates Positive momentum. The RSI at 49.10 is Neutral, neither overbought nor oversold. The STOCH value of 27.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for WAT.
Waters Risk Analysis
Waters disclosed 2 risk factors in its most recent earnings report. Waters reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
1 New RiskWaters Peers Comparison
Overall Rating
TMO76.9Outperform
A75Outperform
MTD75Outperform
RVTY74Outperform
DHR73Outperform
WAT59Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | $256.15B | 36.40 | 13.31% | 0.27% | 8.27% | 9.59% | |
| 75Outperform | $48.75B | 34.01 | 20.47% | 0.59% | 8.60% | 19.07% | |
| 75Outperform | $34.36B | 37.38 | 9999.00% | ― | 6.51% | 15.03% | |
| 74Outperform | $16.62B | 66.18 | 3.50% | 0.19% | 4.56% | 13.22% | |
| 73Outperform | $161.75B | 37.78 | 8.18% | 0.66% | 5.52% | 25.53% | |
| 59Neutral | $44.56B | 192.94 | 0.81% | ― | 80.68% | -78.49% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| WAT | Waters Corp | 453.42 | 76.79 | 20.39% | |
| A | Agilent Technologies | 172.92 | 30.15 | 21.12% | |
| DHR | Danaher Corporation | 229.91 | 6.05 | 2.70% | |
| MTD | Mettler-toledo International | 1727.26 | 330.81 | 23.69% | |
| RVTY | Revvity, Inc. | 148.85 | 56.02 | 60.35% | |
| TMO | Thermo Fisher Scientific | 691.33 | 117.32 | 20.44% |
Waters Corporate Events
Waters Announces Leadership Change in Analytical Sciences Division
NeutralOn August 17, 2026, Waters Corporation announced that Robert L. Carpio III had decided to resign from his role as Senior Vice President of the Waters Analytical Sciences Division to pursue other opportunities, relinquishing his duties effective Augus...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026
